Prostate Cancer - Results from #1300

Trajectory of Depression among Prostate Cancer Patients: A Secondary Analysis of a Randomized Controlled Trial. March 1, 2024

Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients. February 29, 2024

Prostatic Artery Embolization in Patients with Advanced Prostate Cancer: A Prospective Single Center Pilot Study. February 29, 2024

Radical prostatectomy cancer grade and percentage of Gleason pattern 4 estimated by global vs individual tumor grading correlate differently with the risk of biochemical recurrence in Grade Group 2 and 3 cancers. February 29, 2024

Thio-2 inhibits key signaling pathways required for the development and progression of castration resistant prostate cancer. February 29, 2024

Detection of PSMA expression on circulating tumor cells by blood-based liquid biopsy in prostate cancer. February 29, 2024

Decoding the Epigenetics and Chromatin Loop Dynamics of Androgen Receptor-Mediated Transcription. February 29, 2024

Meta-analyses of mouse and human prostate single-cell transcriptomes reveal widespread epithelial plasticity in tissue regression, regeneration, and cancer. February 29, 2024

A prospective study of birth weight and prostate cancer risk and mortality in the Health Professionals Follow-up Study. February 28, 2024

Pencil Beam Scanning Proton Bragg Peak Conformal FLASH in Prostate Cancer Stereotactic Body Radiotherapy. February 28, 2024

Cancer cells employ lipid droplets to survive toxic stress. February 28, 2024

One-year clinical outcomes of MR-guided stereotactic body radiation therapy with rectal spacer for patients with localized prostate cancer. February 28, 2024

Single cell-transcriptomic analysis informs the lncRNA landscape in metastatic castration resistant prostate cancer. February 28, 2024

Stroma-specific gene expression signature identifies prostate cancer subtype with high recurrence risk. February 28, 2024

Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS. February 27, 2024

Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING). February 27, 2024

Variation in communication of side effects in prostate cancer treatment consultations. February 27, 2024

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. February 27, 2024

Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate Cancer. February 27, 2024

Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1). February 27, 2024

Page 66 of 1436